These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 12660398)

  • 1. Management of latent tuberculosis infection in immigrants.
    Marks SM; Ijaz K; Iademarco MF
    N Engl J Med; 2003 Mar; 348(13):1289-92; author reply 1289-92. PubMed ID: 12660398
    [No Abstract]   [Full Text] [Related]  

  • 2. Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States.
    Khan K; Muennig P; Behta M; Zivin JG
    N Engl J Med; 2002 Dec; 347(23):1850-9. PubMed ID: 12466510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of latent tuberculosis infection in immigrants.
    Sterling T; Munsiff SS; Frieden TR
    N Engl J Med; 2003 Mar; 348(13):1289-92; author reply 1289-92. PubMed ID: 12661573
    [No Abstract]   [Full Text] [Related]  

  • 4. Management of latent tuberculosis infection in immigrants.
    Menzies D; Schwartzman K
    N Engl J Med; 2003 Mar; 348(13):1289-92; author reply 1289-92. PubMed ID: 12661572
    [No Abstract]   [Full Text] [Related]  

  • 5. Considering the role of four months of rifampin in the treatment of latent tuberculosis infection.
    Reichman LB; Lardizabal A; Hayden CH
    Am J Respir Crit Care Med; 2004 Oct; 170(8):832-5. PubMed ID: 15297274
    [No Abstract]   [Full Text] [Related]  

  • 6. Rifampin and pyrazinamide for treatment of latent tuberculosis infection: is it safe?
    Jasmer RM; Daley CL
    Am J Respir Crit Care Med; 2003 Mar; 167(6):809-10. PubMed ID: 12623855
    [No Abstract]   [Full Text] [Related]  

  • 7. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial.
    Ijaz K; McElroy PD; Navin TR
    Clin Infect Dis; 2004 Jul; 39(2):289. PubMed ID: 15307044
    [No Abstract]   [Full Text] [Related]  

  • 8. Rifampicin/pyrazinamide therapy should not be used for latent tuberculosis infection.
    Garca-Doval I
    J Am Acad Dermatol; 2004 May; 50(5):801; author reply 801-2. PubMed ID: 15097974
    [No Abstract]   [Full Text] [Related]  

  • 9. In reply.
    Reves RR
    Int J Tuberc Lung Dis; 2015 Apr; 19(4):495. PubMed ID: 25860012
    [No Abstract]   [Full Text] [Related]  

  • 10. The best approach to reintroducing tuberculosis treatment after hepatotoxicity is still open to debate.
    Chang KC; Leung CC
    Clin Infect Dis; 2010 Aug; 51(3):366-7; author reply 367-8. PubMed ID: 20597681
    [No Abstract]   [Full Text] [Related]  

  • 11. Is the recommendation not to use rifampin plus pyrazinamide for latent tuberculosis treatment always imperative?
    Cazzadori A; Allegranzi B; Scardigli A; Favari F; Concia E
    Chest; 2004 Aug; 126(2):657-8. PubMed ID: 15302765
    [No Abstract]   [Full Text] [Related]  

  • 12. Safe and effective treatment for patients with isoniazid drug resistance.
    Phillips PP; Lipman MC
    Int J Tuberc Lung Dis; 2015 Apr; 19(4):494-5. PubMed ID: 25860010
    [No Abstract]   [Full Text] [Related]  

  • 13. Drugs for tuberculosis.
    Med Lett Drugs Ther; 1988 Apr; 30(763):43-4. PubMed ID: 3352531
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety and completion rate of short-course therapy for treatment of latent tuberculosis infection.
    Cook PP; Maldonado RA; Yarnell CT; Holbert D
    Clin Infect Dis; 2006 Aug; 43(3):271-5. PubMed ID: 16804838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of rifampin for 4 months and isoniazid for 6 months in the treatment of tuberculosis infection.
    Pina JM; Clotet L; Ferrer A; Sala MR; Garrido P; Salleras L; Domínguez A
    Respir Med; 2013 May; 107(5):768-77. PubMed ID: 23490222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rifampin and pyrazinamide for treatment of latent tuberculosis infection.
    Cook PP
    Clin Infect Dis; 2006 Mar; 42(6):892; author reply 892-3. PubMed ID: 16477576
    [No Abstract]   [Full Text] [Related]  

  • 17. Severe or fatal liver injury in 50 patients in the United States taking rifampin and pyrazinamide for latent tuberculosis infection.
    Ijaz K; Jereb JA; Lambert LA; Bower WA; Spradling PR; McElroy PD; Iademarco MF; Navin TR; Castro KG
    Clin Infect Dis; 2006 Feb; 42(3):346-55. PubMed ID: 16392079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial.
    Jasmer RM; Snyder DC; Saukkonen JJ; Hopewell PC; Bernardo J; King MD; Kawamura LM; Daley CL;
    Clin Infect Dis; 2004 Feb; 38(3):363-9. PubMed ID: 14727206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection.
    McElroy PD; Ijaz K; Lambert LA; Jereb JA; Iademarco MF; Castro KG; Navin TR
    Clin Infect Dis; 2005 Oct; 41(8):1125-33. PubMed ID: 16163632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and tolerability of intermittent rifampin/pyrazinamide for the treatment of latent tuberculosis infection in prisoners.
    Chaisson RE; Armstrong J; Stafford J; Golub J; Bur S
    JAMA; 2002 Jul; 288(2):165-6. PubMed ID: 12095379
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.